HOOSIER CANCER RESEARCH NETWORK

Funding Organization

Temporal Graph

Map of Science

Research

Awards Grant

UAB 1428 – A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HOG Trial)

UAB 1661: Randomized Phase II Trial Comparing Sequential First-Line Sunitinib and Second-Line Avelumab Versus First-Line Avelumab and Second-Line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial

XUAB 2167 - A Phase II Circulating Tumor DNA Enriched, Gnomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE): HCRN BRE18-334

XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

XUAB2147-Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases